Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin for Consolidation of First Remission of Patients With High-Risk Neuroblastoma: A Phase II Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03033303

Title field or adapter rule

{'original_value': 'Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin for Consolidation of First Remission of Patients With High-Risk Neuroblastoma: A Phase II Study', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T01:06:25.752052+00:00

Published At

2026-10-30T00:00:00+00:00

Record Updated At

2026-10-30

Results Posted At

2026-10-30

Source Retrieved At

2026-10-31T01:06:25.053101+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Neuroblastoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-30", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT03033303"

protocolSection.identificationModule.officialTitle

"Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin for Consolidation of First Remission of Patients With High-Risk Neuroblastoma: A Phase II Study"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2026-10-30", "type": "ACTUAL"}

Study condition terms

• Neuroblastoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Hu3F8/GM-CSF Plus Isotretinoin'], 'description': 'Day 1: hu3F8 infused iv over \\~30 to 90 minutes. Day 3: hu3F8 infused iv over \\~30 to 90 minutes. Day 5: hu3F8 infused iv over \\~30 to 90 minutes.', 'name': 'Hu3F8', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Hu3F8/GM-CSF Plus Isotretinoin'], 'description': 'Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.', 'name': 'GM-CSF', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Hu3F8/GM-CSF Plus Isotretinoin'], 'description': 'Isotretinoin is administered at 160 mg/m2/d, divided into two doses, x14 days.', 'name': 'Isotretinoin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• GM-CSF (protocolSection.armsInterventionsModule.interventions[].name)
• Isotretinoin (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.